Latest Pharma Insights
Merck & Co.’s Enlicitide Raises The Bar For Oral Lipid Lowering
Detailed clinical trial data presented at AHA positions the oral PCSK9 inhibitor on par with injectable drugs on efficacy, but the competitive dynamics remain intense.
Scrip - November 10, 2025
Detailed clinical trial data presented at AHA positions the oral PCSK9 inhibitor on par with injectable drugs on efficacy, but the competitive dynamics remain intense.
Scrip - November 10, 2025
Prosthetics: Firms Like Unhindr And Esper Shape Market On the Cusp of Great Change
The prosthetics market is evolving due to an increase in amputees from war and disease. Unhindr has developed a novel prostetic liner that can reduce the risk of further injury, while Esper is crafting advanced hand implants for Ukraine's front-line soldiers.
Medtech Insight - November 10, 2025
The prosthetics market is evolving due to an increase in amputees from war and disease. Unhindr has developed a novel prostetic liner that can reduce the risk of further injury, while Esper is crafting advanced hand implants for Ukraine's front-line soldiers.
Medtech Insight - November 10, 2025
Madrigal May Have Head Start On Demonstrating Cirrhosis Benefit
At AASLD, Madrigal presented Phase III open-label data showing resmetirom can improve liver stiffness and other liver health measures in patients with cirrhosis. It hopes for outcomes data in 2027.
Scrip - November 10, 2025
At AASLD, Madrigal presented Phase III open-label data showing resmetirom can improve liver stiffness and other liver health measures in patients with cirrhosis. It hopes for outcomes data in 2027.
Scrip - November 10, 2025
Deals Shaping The Medtech And Diagnostics Industries, October 2025
An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.
Medtech Insight - November 10, 2025
An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.
Medtech Insight - November 10, 2025
Cogent Hits Mark In Phase III GIST Trial Of Bezuclastinib
The PEAK study showed a high median progression-free survival and objective response rate in second-line disease for bezuclastinib combined with sunitinib.
Scrip - November 10, 2025
The PEAK study showed a high median progression-free survival and objective response rate in second-line disease for bezuclastinib combined with sunitinib.
Scrip - November 10, 2025
California Firm Too Busy To Defend Ad Claims For NAD+ Supplement It Previously Marketed
Virgin Scent didn’t respond to NAD attorneys’ “repeated outreach attempts” asking for evidence supporting ad claims for Artnaturals NAD+ challenged by another NAD+ supplement marketer, Reus Research.
HBW Insight - November 10, 2025
Virgin Scent didn’t respond to NAD attorneys’ “repeated outreach attempts” asking for evidence supporting ad claims for Artnaturals NAD+ challenged by another NAD+ supplement marketer, Reus Research.
HBW Insight - November 10, 2025
Novo-Emcure Semaglutide Deal Clever Counter To Indian Rivals, Follows Lilly-Cipla Pact
Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year
Scrip - November 10, 2025
Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year
Scrip - November 10, 2025
Cipla Acquires Inzpera To Grow Indian Consumer Health Offering
Cipla has paid Tata Industries around $12.5m for Inzpera Healthsciences to grow its consumer health portfolio.
HBW Insight - November 10, 2025
Cipla has paid Tata Industries around $12.5m for Inzpera Healthsciences to grow its consumer health portfolio.
HBW Insight - November 10, 2025
MeiraGTx Gene Therapy Catches Lilly’s Eye In $475m Pact
Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene thewrapy for a rare form of childhood blindness.
Scrip - November 10, 2025
Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene thewrapy for a rare form of childhood blindness.
Scrip - November 10, 2025
Two Big MS Wins For Fenebrutinib But Roche Not Declaring Victory Yet
The Swiss company could have a best-in-class oral BTK inhibitor for multiple sclerosis but needs more data before it can reassure on safety and efficacy.
Scrip - November 10, 2025
The Swiss company could have a best-in-class oral BTK inhibitor for multiple sclerosis but needs more data before it can reassure on safety and efficacy.
Scrip - November 10, 2025
How Rare Disease Advocates Are Reshaping Gene Therapy Development
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
In Vivo - November 10, 2025
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
In Vivo - November 10, 2025
Mifepristone: Judge Orders US FDA To Rethink Need For REMS Restrictions
A federal judge in Hawaii ruled the FDA failed to consider statutory factors relevant to the REMS and provide a “reasoned explanation” for its restrictive treatment of the drug, but remand could result in an agency determination that more extensive restrictions are needed.
Generics Bulletin - November 10, 2025
A federal judge in Hawaii ruled the FDA failed to consider statutory factors relevant to the REMS and provide a “reasoned explanation” for its restrictive treatment of the drug, but remand could result in an agency determination that more extensive restrictions are needed.
Generics Bulletin - November 10, 2025
Small Biotech, Big Breakthrough: Abivax Enters A New Era
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
In Vivo - November 10, 2025
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
In Vivo - November 10, 2025
Dealmaking Quarterly Statistics, Q3 2025
During Q3, biopharma merger and acquisition deal value reached $40.7bn and drew in $66.5bn in potential deal value from alliances. Device company M&A values reached $6.4bn, while in vitro diagnostics and research tools players’ M&A activity totaled $15m.
In Vivo - November 10, 2025
During Q3, biopharma merger and acquisition deal value reached $40.7bn and drew in $66.5bn in potential deal value from alliances. Device company M&A values reached $6.4bn, while in vitro diagnostics and research tools players’ M&A activity totaled $15m.
In Vivo - November 10, 2025
Alvotech Grabs UK Approval For Simponi Biosimilar After FDA Knockback
Alvotech forges ahead with its golimumab biosimilar after receiving approval in the UK, as the US market will have to wait.
Generics Bulletin - November 10, 2025
Alvotech forges ahead with its golimumab biosimilar after receiving approval in the UK, as the US market will have to wait.
Generics Bulletin - November 10, 2025
EU, UK & Switzerland Speed Up Trials To Regain Global Edge
Amid a decline in global clinical research share, the EU, UK and Switzerland have launched initiatives for fast-track reviews of clinical trial applications and set ambitious targets to shorten trial setup times.
In Vivo - November 10, 2025
Amid a decline in global clinical research share, the EU, UK and Switzerland have launched initiatives for fast-track reviews of clinical trial applications and set ambitious targets to shorten trial setup times.
In Vivo - November 10, 2025
Pipeline Watch: Two Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2025
Who’s Hired? Hikma Seeks New Injectables Chief As Larkins Steps Down
Hikma has started searching for a new Injectables head after Bill Larkins stepped down, at the same time as the firm has begun a reorganization of its R&D operations. Meanwhile, Stada has named a new head of Germany and Viatris has promoted a key executive in Europe.
Generics Bulletin - November 10, 2025
Hikma has started searching for a new Injectables head after Bill Larkins stepped down, at the same time as the firm has begun a reorganization of its R&D operations. Meanwhile, Stada has named a new head of Germany and Viatris has promoted a key executive in Europe.
Generics Bulletin - November 10, 2025
‘Going Beyond’ – Celltrion USA Explains How It Is Building On Biosimilars
In an exclusive interview with Generics Bulletin, Celltrion USA executives Tom Nusbickel and Juby Jacob-Nara discuss recent biosimilar launches, streamlining, moves into more innovative areas, and how Celltrion’s recent commitment to US manufacturing shows that the firm is “in it for the long run.”
Generics Bulletin - November 10, 2025
In an exclusive interview with Generics Bulletin, Celltrion USA executives Tom Nusbickel and Juby Jacob-Nara discuss recent biosimilar launches, streamlining, moves into more innovative areas, and how Celltrion’s recent commitment to US manufacturing shows that the firm is “in it for the long run.”
Generics Bulletin - November 10, 2025
Viatris’ Indore Plant Remediation ‘Largely Complete’ As FDA Re-Inspection Looms
Viatris says initial corrective work at its oral solid dose site in India is “substantially complete” and that it has met with the FDA to discuss next steps following last year’s warning letter and import alert.
Generics Bulletin - November 10, 2025
Viatris says initial corrective work at its oral solid dose site in India is “substantially complete” and that it has met with the FDA to discuss next steps following last year’s warning letter and import alert.
Generics Bulletin - November 10, 2025
Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?
Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?
Scrip - November 10, 2025
Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?
Scrip - November 10, 2025
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Pfizer’s unwavering pursuit of Metsera; Lilly’s obesity momentum; Merck & Co.’s MFN negotiations; Novartis’s promising Sjögren’s results; and the rising Chinese pressure on US innovation.
Scrip - November 10, 2025
In this week's episode: Pfizer’s unwavering pursuit of Metsera; Lilly’s obesity momentum; Merck & Co.’s MFN negotiations; Novartis’s promising Sjögren’s results; and the rising Chinese pressure on US innovation.
Scrip - November 10, 2025
Weight Loss Emerging As Herbalife Protocol For Sales With Pro2Col App Launch Approaching
MultiBurn supplement launch “is creating kind of a new focus I would say around weight loss, where quite honestly, we’ve been probably more of a healthy active lifestyle,” says CEO Stephan Gratziani. Pro2Col app for personalized wellness launching before January.
HBW Insight - November 10, 2025
MultiBurn supplement launch “is creating kind of a new focus I would say around weight loss, where quite honestly, we’ve been probably more of a healthy active lifestyle,” says CEO Stephan Gratziani. Pro2Col app for personalized wellness launching before January.
HBW Insight - November 10, 2025
TikTok Shop’s US Skin Care, Fragrance, Makeup Sales Reach $825M January-August – Market Defense
TikTok Shop’s US skin care sales reached $309m, with popular searches for Korean skin care and hyperpigmentation suggesting the types of products that are driving sales.
HBW Insight - November 10, 2025
TikTok Shop’s US skin care sales reached $309m, with popular searches for Korean skin care and hyperpigmentation suggesting the types of products that are driving sales.
HBW Insight - November 10, 2025
Merck & Co.’s Enlicitide Raises The Bar For Oral Lipid Lowering
Detailed clinical trial data presented at AHA positions the oral PCSK9 inhibitor on par with injectable drugs on efficacy, but the competitive dynamics remain intense.
Scrip - November 10, 2025
Detailed clinical trial data presented at AHA positions the oral PCSK9 inhibitor on par with injectable drugs on efficacy, but the competitive dynamics remain intense.
Scrip - November 10, 2025
Madrigal May Have Head Start On Demonstrating Cirrhosis Benefit
At AASLD, Madrigal presented Phase III open-label data showing resmetirom can improve liver stiffness and other liver health measures in patients with cirrhosis. It hopes for outcomes data in 2027.
Scrip - November 10, 2025
At AASLD, Madrigal presented Phase III open-label data showing resmetirom can improve liver stiffness and other liver health measures in patients with cirrhosis. It hopes for outcomes data in 2027.
Scrip - November 10, 2025
Cogent Hits Mark In Phase III GIST Trial Of Bezuclastinib
The PEAK study showed a high median progression-free survival and objective response rate in second-line disease for bezuclastinib combined with sunitinib.
Scrip - November 10, 2025
The PEAK study showed a high median progression-free survival and objective response rate in second-line disease for bezuclastinib combined with sunitinib.
Scrip - November 10, 2025
Novo-Emcure Semaglutide Deal Clever Counter To Indian Rivals, Follows Lilly-Cipla Pact
Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year
Scrip - November 10, 2025
Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year
Scrip - November 10, 2025
MeiraGTx Gene Therapy Catches Lilly’s Eye In $475m Pact
Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene thewrapy for a rare form of childhood blindness.
Scrip - November 10, 2025
Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene thewrapy for a rare form of childhood blindness.
Scrip - November 10, 2025
Two Big MS Wins For Fenebrutinib But Roche Not Declaring Victory Yet
The Swiss company could have a best-in-class oral BTK inhibitor for multiple sclerosis but needs more data before it can reassure on safety and efficacy.
Scrip - November 10, 2025
The Swiss company could have a best-in-class oral BTK inhibitor for multiple sclerosis but needs more data before it can reassure on safety and efficacy.
Scrip - November 10, 2025
Pipeline Watch: Two Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2025
Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?
Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?
Scrip - November 10, 2025
Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?
Scrip - November 10, 2025
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Pfizer’s unwavering pursuit of Metsera; Lilly’s obesity momentum; Merck & Co.’s MFN negotiations; Novartis’s promising Sjögren’s results; and the rising Chinese pressure on US innovation.
Scrip - November 10, 2025
In this week's episode: Pfizer’s unwavering pursuit of Metsera; Lilly’s obesity momentum; Merck & Co.’s MFN negotiations; Novartis’s promising Sjögren’s results; and the rising Chinese pressure on US innovation.
Scrip - November 10, 2025
Prosthetics: Firms Like Unhindr And Esper Shape Market On the Cusp of Great Change
The prosthetics market is evolving due to an increase in amputees from war and disease. Unhindr has developed a novel prostetic liner that can reduce the risk of further injury, while Esper is crafting advanced hand implants for Ukraine's front-line soldiers.
Medtech Insight - November 10, 2025
The prosthetics market is evolving due to an increase in amputees from war and disease. Unhindr has developed a novel prostetic liner that can reduce the risk of further injury, while Esper is crafting advanced hand implants for Ukraine's front-line soldiers.
Medtech Insight - November 10, 2025
Deals Shaping The Medtech And Diagnostics Industries, October 2025
An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.
Medtech Insight - November 10, 2025
An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.
Medtech Insight - November 10, 2025
California Firm Too Busy To Defend Ad Claims For NAD+ Supplement It Previously Marketed
Virgin Scent didn’t respond to NAD attorneys’ “repeated outreach attempts” asking for evidence supporting ad claims for Artnaturals NAD+ challenged by another NAD+ supplement marketer, Reus Research.
HBW Insight - November 10, 2025
Virgin Scent didn’t respond to NAD attorneys’ “repeated outreach attempts” asking for evidence supporting ad claims for Artnaturals NAD+ challenged by another NAD+ supplement marketer, Reus Research.
HBW Insight - November 10, 2025
Cipla Acquires Inzpera To Grow Indian Consumer Health Offering
Cipla has paid Tata Industries around $12.5m for Inzpera Healthsciences to grow its consumer health portfolio.
HBW Insight - November 10, 2025
Cipla has paid Tata Industries around $12.5m for Inzpera Healthsciences to grow its consumer health portfolio.
HBW Insight - November 10, 2025
Weight Loss Emerging As Herbalife Protocol For Sales With Pro2Col App Launch Approaching
MultiBurn supplement launch “is creating kind of a new focus I would say around weight loss, where quite honestly, we’ve been probably more of a healthy active lifestyle,” says CEO Stephan Gratziani. Pro2Col app for personalized wellness launching before January.
HBW Insight - November 10, 2025
MultiBurn supplement launch “is creating kind of a new focus I would say around weight loss, where quite honestly, we’ve been probably more of a healthy active lifestyle,” says CEO Stephan Gratziani. Pro2Col app for personalized wellness launching before January.
HBW Insight - November 10, 2025
TikTok Shop’s US Skin Care, Fragrance, Makeup Sales Reach $825M January-August – Market Defense
TikTok Shop’s US skin care sales reached $309m, with popular searches for Korean skin care and hyperpigmentation suggesting the types of products that are driving sales.
HBW Insight - November 10, 2025
TikTok Shop’s US skin care sales reached $309m, with popular searches for Korean skin care and hyperpigmentation suggesting the types of products that are driving sales.
HBW Insight - November 10, 2025
Mifepristone: Judge Orders US FDA To Rethink Need For REMS Restrictions
A federal judge in Hawaii ruled the FDA failed to consider statutory factors relevant to the REMS and provide a “reasoned explanation” for its restrictive treatment of the drug, but remand could result in an agency determination that more extensive restrictions are needed.
Generics Bulletin - November 10, 2025
A federal judge in Hawaii ruled the FDA failed to consider statutory factors relevant to the REMS and provide a “reasoned explanation” for its restrictive treatment of the drug, but remand could result in an agency determination that more extensive restrictions are needed.
Generics Bulletin - November 10, 2025
Alvotech Grabs UK Approval For Simponi Biosimilar After FDA Knockback
Alvotech forges ahead with its golimumab biosimilar after receiving approval in the UK, as the US market will have to wait.
Generics Bulletin - November 10, 2025
Alvotech forges ahead with its golimumab biosimilar after receiving approval in the UK, as the US market will have to wait.
Generics Bulletin - November 10, 2025
Who’s Hired? Hikma Seeks New Injectables Chief As Larkins Steps Down
Hikma has started searching for a new Injectables head after Bill Larkins stepped down, at the same time as the firm has begun a reorganization of its R&D operations. Meanwhile, Stada has named a new head of Germany and Viatris has promoted a key executive in Europe.
Generics Bulletin - November 10, 2025
Hikma has started searching for a new Injectables head after Bill Larkins stepped down, at the same time as the firm has begun a reorganization of its R&D operations. Meanwhile, Stada has named a new head of Germany and Viatris has promoted a key executive in Europe.
Generics Bulletin - November 10, 2025
‘Going Beyond’ – Celltrion USA Explains How It Is Building On Biosimilars
In an exclusive interview with Generics Bulletin, Celltrion USA executives Tom Nusbickel and Juby Jacob-Nara discuss recent biosimilar launches, streamlining, moves into more innovative areas, and how Celltrion’s recent commitment to US manufacturing shows that the firm is “in it for the long run.”
Generics Bulletin - November 10, 2025
In an exclusive interview with Generics Bulletin, Celltrion USA executives Tom Nusbickel and Juby Jacob-Nara discuss recent biosimilar launches, streamlining, moves into more innovative areas, and how Celltrion’s recent commitment to US manufacturing shows that the firm is “in it for the long run.”
Generics Bulletin - November 10, 2025
Viatris’ Indore Plant Remediation ‘Largely Complete’ As FDA Re-Inspection Looms
Viatris says initial corrective work at its oral solid dose site in India is “substantially complete” and that it has met with the FDA to discuss next steps following last year’s warning letter and import alert.
Generics Bulletin - November 10, 2025
Viatris says initial corrective work at its oral solid dose site in India is “substantially complete” and that it has met with the FDA to discuss next steps following last year’s warning letter and import alert.
Generics Bulletin - November 10, 2025
How Rare Disease Advocates Are Reshaping Gene Therapy Development
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
In Vivo - November 10, 2025
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
In Vivo - November 10, 2025
Small Biotech, Big Breakthrough: Abivax Enters A New Era
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
In Vivo - November 10, 2025
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
In Vivo - November 10, 2025
Dealmaking Quarterly Statistics, Q3 2025
During Q3, biopharma merger and acquisition deal value reached $40.7bn and drew in $66.5bn in potential deal value from alliances. Device company M&A values reached $6.4bn, while in vitro diagnostics and research tools players’ M&A activity totaled $15m.
In Vivo - November 10, 2025
During Q3, biopharma merger and acquisition deal value reached $40.7bn and drew in $66.5bn in potential deal value from alliances. Device company M&A values reached $6.4bn, while in vitro diagnostics and research tools players’ M&A activity totaled $15m.
In Vivo - November 10, 2025
EU, UK & Switzerland Speed Up Trials To Regain Global Edge
Amid a decline in global clinical research share, the EU, UK and Switzerland have launched initiatives for fast-track reviews of clinical trial applications and set ambitious targets to shorten trial setup times.
In Vivo - November 10, 2025
Amid a decline in global clinical research share, the EU, UK and Switzerland have launched initiatives for fast-track reviews of clinical trial applications and set ambitious targets to shorten trial setup times.
In Vivo - November 10, 2025